LAGUNA HILLS, Calif., April 2026

Anaxiom Corporation has announced encouraging early clinical results from its first-in-human study of the AVOS™ minimally invasive obesity device, marking a significant advancement in the development of non-surgical treatments for obesity and metabolic disease. The initial 12-patient international clinical study demonstrated a strong safety profile with no device-related serious adverse events, alongside promising early signals of weight loss and appetite reduction. These results position the AVOS™ system as a potentially transformative alternative to traditional obesity treatments, including pharmacological therapies and bariatric surgery, while supporting the company’s plans to advance toward a U.S. Early Feasibility Study.

Early Clinical Results Demonstrate Safety and Efficacy

The study represents a critical milestone in validating the clinical potential of minimally invasive obesity interventions, particularly those targeting physiological pathways rather than relying solely on drugs or surgery. In the treated patient cohort, clinicians observed significant appetite suppression and measurable improvements in overall health indicators, suggesting the device’s ability to deliver sustained metabolic benefits. Importantly, the absence of serious adverse events underscores the favorable safety profile, a key requirement for broader adoption in clinical practice.

Physicians involved in the procedures highlighted the ease of integration into standard endovascular workflows, noting that the technique closely resembles widely used catheter-based interventions. This compatibility with existing medical infrastructure could accelerate clinical adoption and scalability, particularly in cardiology and interventional radiology settings where such procedures are routine.

Innovative Endovascular Approach to Appetite Control

Advertisement

cGxPJobs Banner

At the core of this innovation is the AVOS™ device, a catheter-delivered implantable stent designed to be positioned over the celiac artery ostium. By modulating blood flow to targeted gastric regions, the device aims to reduce the production of ghrelin, commonly known as the hunger hormone, thereby decreasing appetite and promoting weight loss. This mechanism of action represents a novel, physiology-based approach that mimics natural metabolic conditions associated with reduced hunger.

The procedure is performed under conscious sedation using minimally invasive techniques, typically within one hour, and has the potential to transition into outpatient surgical settings, significantly improving patient convenience and reducing healthcare costs. Unlike lifelong drug therapies or invasive bariatric surgeries, AVOS™ offers a durable, implant-based solution that addresses obesity at its biological source, aligning with the growing demand for precision and patient-centric treatments.

Advancing Toward U.S. Feasibility and Market Impact

Building on these early findings, Anaxiom is preparing to initiate a U.S. Early Feasibility Study, which will further evaluate the device’s safety and effectiveness in a controlled clinical environment. The company believes that AVOS™ could play a pivotal role in reshaping the obesity treatment landscape, particularly as global obesity rates continue to rise and healthcare systems seek cost-effective, scalable solutions.

By offering a minimally invasive, non-pharmacologic alternative, the technology addresses key limitations associated with existing therapies, including treatment adherence, long-term safety concerns, and procedural risks. Industry experts suggest that such innovations could significantly expand treatment accessibility, especially for patients who are not candidates for surgery or prefer alternatives to chronic medication use. As Anaxiom advances its clinical program, the AVOS™ platform is poised to become a key innovation in the rapidly evolving field of metabolic and obesity care, with the potential to deliver improved patient outcomes and long-term healthcare value.

Source: Anaxiom press release